New prodrugs of metformin do not influence the overall haemostasis potential and integrity of the erythrocyte membrane

Eur J Pharmacol. 2017 Sep 15:811:208-221. doi: 10.1016/j.ejphar.2017.06.011. Epub 2017 Jun 10.

Abstract

Although metformin, an oral anti-diabetic drug, has been found to have multidirectional effects over the past decade, it is characterised by unfavourable pharmacokinetic properties. This study discusses the effects of metformin, phenformin and three prodrugs of metformin on the haemostasis and integrity of Red Blood Cells (RBCs). The influence of examined biguanide derivatives on haemostasis was evaluated spectrophotometrically by clot formation and lysis test (CL-test) at 405nm. The extrinsic and intrinsic coagulation pathway were examined by measuring the PT (Prothrombin Time) and aPTT (Activated Partial Tromboplastin Time). Haemolysis assay, microscopy and flow cytometry studies were used to assess the effect of the tested compounds on RBCs. Although none of the tested biguanide derivatives significantly influenced the overall potential of clot formation and fibrinolysis (CLAUC constants), statistically significant changes were seen in the values of the kinetic parameters of fibrinolysis. Furthermore, only prodrug 2, with an 8-carbon alkyl chain, unfavourably affected RBCs by interaction with the erythrocyte membrane leading to significant haemolysis. Our results provide a further insight into the effects of metformin and its prodrugs on haemostasis and RBCs and underscore the necessity for further research.

Keywords: Biguanides; Coagulation; Fibrinolysis; Haemostasis; Metformin; Prodrugs.

MeSH terms

  • Blood Coagulation / drug effects
  • Erythrocyte Membrane / drug effects*
  • Hemostasis / drug effects*
  • Humans
  • Metformin / metabolism*
  • Prodrugs / metabolism
  • Prodrugs / pharmacology*

Substances

  • Prodrugs
  • Metformin